FACTS: 1) Analyst price target is $2.6 2) AMRS is sector leader 3) Farnesene is expected to grow 30% CAGR the next 8 years per recent report, 4) AMRS is only farnesene producer in the world, 5) Many other new molecules being developed with Gingko Bioworks and Darpa, 6) balance sheet improving with non-core asset sales, 7) Record 3Q and 4Q and 2017 ahead, 8) output from Brotas plant in Brazil sold out for many years, 9) TOTAL owns 31% and so does Temasek, 10) AMRS is tyhe darling from the Bill and Linda Gates foundation
50c is way way toooooo cheap!!!!!
I see $1 plus after 3Q in 6 weeks